Product Marks. If, following any termination after the License Effective Date, BN notifies BMS in writing within [***] after the date of termination that BN wishes to acquire any Product Xxxx used in connection with the terminated Product(s), BMS shall, subject to Section 12.7(l), assign to BN, or cause the assignment to BN of, all rights in and to such Product Xxxx for the terminated Product(s) in the terminated Region(s), together with all associated goodwill. It is understood that such assignment shall not include the BMS name or trademark for the BMS company itself, or any other trademark owned or Controlled by BMS and not specific to a Product. BMS will provide such written confirmation and execute such instruments as BN may reasonably request to confirm BN’s title, rights and interests and will reasonably cooperate with BN in registering such assignments with appropriate Governmental Authorities. Any Product Marks that BN does not request to have assigned to it in accordance with this Section 12.7(e) shall remain the property of BMS and BMS shall be free to use such Product Marks anywhere in the world, in any manner and with any product as it may determine in its sole discretion, without further consulting BN.
Product Marks. Sanofi shall have the right to Commercialize the Products in the Licensed Territory, in accordance with Applicable Law, using (i) the corporate Trademarks of Sanofi and its Affiliates, Sublicensees and Distributors and (ii) subject to Section 11.5(a)(ii), any other Trademarks it determines appropriate for such Products in such countries (such Trademarks in clause (ii), the “Product Marks”), which may vary by country or within a country, provided that the Parties shall coordinate in good faith a global branding strategy with respect to the Products through the JCC pursuant to Section 2.4(a). Sanofi shall own all rights in the Product Marks and shall have the sole right to register, prosecute and maintain the Product Marks using counsel of its own choice in the countries and regions in the Licensed Territory that it determines reasonably necessary, at Sanofi’s cost and expense.
Product Marks. Alliqua shall have the right to brand the Licensed Products and create all Licensed Product labels using Alliqua-related trademarks and any other trademarks and trade names it determines appropriate (including the CCT Marks as set forth in Section 8.6(b) below) for the Licensed Products, which may vary by country or within a country (collectively, the “Product Marks”). The Parties acknowledge and agree that the Licensed Products shall be co-branded as mutually agreed upon in writing by the Parties and that Alliqua shall give the proper attribution on each Licensed Product to CCT as provider of the CCT Technology or as otherwise mutually agreed upon by the Parties. The Parties shall mutually agree upon the form and substance of such attribution rights. In the event that Alliqua desires to brand a Licensed Product using an alternative name, Alliqua shall first propose such alternative name to CCT, which name may be approved by CCT in its sole discretion. For the avoidance of doubt, in no event may Alliqua brand a Licensed Product under an alternative name without the prior written consent of CCT.
Product Marks. Oncoheroes may brand Product in the Licensed Field in the Territory using trademarks, logos, and trade names it determines appropriate (the “Product Marks”). Oncoheroes owns all rights in the Product Marks and shall register and maintain the Product Marks that it determines reasonably necessary, at Oncoheroes’ cost and expense.
Product Marks. Each Party will have the right to Commercialize the Licensed Product in its respective territory using trademarks, logos, and trade names that it determines appropriate, which may vary by region or within a region (“Product Marks”). Each Party will solely own all rights, title, and interests in and to any Product Marks adopted for use with the Licensed Product in its respective territory, including all goodwill related thereto, and will be responsible for the registration, filing, maintenance and enforcement of such Product Marks in its respective territory.
Product Marks. 10.5.1 Bayer shall be responsible for the selection, registration and maintenance of all Product Marks including the trade name and logo to be used to Commercialize the Licensed Product in the Field in the Territory. Bayer shall own and control such Product Marks and pay all relevant costs thereto.
Product Marks. At Licensor’s request, Xxxxxxx will assign to Licensor, all worldwide rights in and to any and all Product Marks used to Commercialize each Reverted Product (but excluding any corporate names and logos of Xxxxxxx), including all trademark applications and registrations therefor. [***] related to the assignments, including recordal of the same. For a period of up to [***] months after the termination date, [***], (i) Xxxxxxx shall provide to Licensor the necessary information to permit Licensor to effect and perfect the transfer of the applications and registrations of the Product Marks and (ii) Xxxxxxx shall reasonably cooperate with Licensor in executing appropriate documents to effectuate the transfer or assignment for the Product Marks worldwide that are in the name of Xxxxxxx or any of its Affiliates. After such period, Xxxxxxx shall have no further obligation with respect to the matters covered by this Section.
Product Marks. The parties shall, via the JDC, closely coordinate with respect to the selection and use of Product-specific trademarks in the parties’ respective territories (“Product Marks”), provided that: (i) ANTHERA shall have the sole right to select the Product Trademarks for use in connection with the marketing and sale of Product in the ANTHERA Territory (“ANTHERA Product Marks”), and ANTHERA shall own and retain all right, title and interest in and to the ANTHERA Product Marks, and all goodwill associated with or attached to the ANTHERA Product Marks arising out of the use thereof by ANTHERA, its Affiliates and Third Party licensees shall inure to the benefit of ANTHERA; and (ii) ZENYAKU shall have the sole right to select the Product Trademarks for use in connection with the marketing and sale of Product in the ZENYAKU Territory (“ZENYAKU Product Marks”), and ZENYAKU shall own and retain all right, title and interest in and to the ZENYAKU Product Marks, and all goodwill associated with or attached to the ZENYAKU Product Marks arising out of the use thereof by ZENYAKU, its Affiliates and Sublicensees shall inure to the benefit of ZENYAKU. Notwithstanding the foregoing, neither party shall select as a Product Xxxx any trademark that incorporates, or is confusingly similar to, any corporate trade name, registered trademark or logo of the other party, without the other party’s prior written approval. If the parties wish to use the same or similar Product Xxxx in the ANTHERA Territory and the ZENYAKU Territory, any such use shall be on terms and conditions to be mutually agreed by the parties in writing, provided however that the parties hereby agree that each party shall be the owner of the selected Product Xxxx in its respective territory and bear the costs and expenses associated with the registration, maintenance and defence of such Product Xxxx in its territory. *** Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission.
Product Marks. Sanuwave shall have the right to brand the Licensed Products and create all Licensed Product labels using Sanuwave-related trademarks and any other trademarks and trade names it determines appropriate (including the Celularity Marks as set forth in Section 7.6(b) below) for the Licensed Products, which may vary by country or within a country (collectively, the “Product Marks”). The Parties acknowledge and agree that the Licensed Products shall be co-branded as mutually agreed upon in writing by the Parties and that Sanuwave shall give the proper attribution on each Licensed Product to Celularity as provider of the Celularity Technology or as otherwise mutually agreed upon by the Parties. The Parties shall mutually agree upon the form and substance of such attribution rights. In the event that Sanuwave desires to brand a Licensed Product using an alternative name, Sanuwave shall first propose such alternative name to Celularity and Celularity may provide comments on the alternative name, which shall be considered in good faith by Sanuwave. For clarity, Sanuwave has the right to brand Biovance and Interfyl using alternative names and Sanuwave’s Product Marks (excluding the Celularity Marks) provided that Sanuwave shall pay for the costs associated with such branding, including design, labor and material costs and expenses.
Product Marks. “Product Marks” shall have the meaning set forth in Section 1.1.
